inno.N said it would develop “global” anticancer treatment jointly with Voronoi, a company specializing in researching and developing new drugs. 

The pipeline, VRN061782, is a selective RET (rearranged during transfection) drug. It works by blocking gene activity if RET genes mutate or cancer occurs from combining with other genes. 

According to the inno.N, a bio-healthcare company, the anticancer drug belongs to the next-generation family, of which only two products have been launched worldwide. Experts said that the market is expected to grow to 2 trillion won ($1.8 billion) by 2026. 

inno.N said it would develop selective RET (rearranged during transfection) anticancer drug jointly with Voronoi. (inno.N)
inno.N said it would develop selective RET (rearranged during transfection) anticancer drug jointly with Voronoi. (inno.N)

inno.N recently introduced new drug material from Voronoi to conduct clinical trials in 2022 and develop it as the key pipeline to compete globally. The company selected the new drug material following its licensing out of the K-CAB tablet, a gastroesophageal reflux disease therapy, to China, a company official told Korea Biomedical Review. The company did not disclose the amount of the contract's upfront.  

Inno.N’s purpose is to develop a customized target anticancer drug that selectively targets cancer cells with identical biomarkers in the cancer spot, including RET gene mutation, lung cancer and thyroid cancer. 

Ultimately, it aims to develop the best-in-class new anticancer pipeline of the drug family that overcomes resistance and is considered safe. The pipeline has already proved through non-clinical animal testing, according to inno.N.

“We plan to enter the global anticancer therapy market based on synergy made with Voronoi’s excellent drug research experience. We will secure various disease pipelines through open innovation,” inno.N CEO Kang Seok-hee said.

Voronoi CEO Kim Dae-kwon also said, “I am grateful to cooperate with inno.N, which has rich experience in clinical trials. We have proved the efficacy of VORONOMICS®, a discovery platform we established through the partnership with inno.N.”
 

Copyright © KBR Unauthorized reproduction, redistribution prohibited